Aspirin cuts clot risk by a third

Aspirin is a viable alternative for preventing recurring venous thromboembolism (VTE) in patients who are not candidates for long-term anticoagulation, say Sydney researchers.

Their research published in the journal Circulation shows that in patients with a first unprovoked VTE who have stopped initial anticoagulation, daily 100mg aspirin lowers the risk of recurring VTE by 32%, as well as deep-vein thrombosis and pulmonary embolism by 34%.

Aspirin also reduced the risk of myocardial